PH12014502405A1 - Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carb on yl}-2,2-dimethylpropyl]carbamate - Google Patents
Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carb on yl}-2,2-dimethylpropyl]carbamateInfo
- Publication number
- PH12014502405A1 PH12014502405A1 PH12014502405A PH12014502405A PH12014502405A1 PH 12014502405 A1 PH12014502405 A1 PH 12014502405A1 PH 12014502405 A PH12014502405 A PH 12014502405A PH 12014502405 A PH12014502405 A PH 12014502405A PH 12014502405 A1 PH12014502405 A1 PH 12014502405A1
- Authority
- PH
- Philippines
- Prior art keywords
- carbamoyl
- ethenylcyclopropyl
- cyclopropylsulfonyl
- dimethylpropyl
- dimethylethyl
- Prior art date
Links
- 239000007963 capsule composition Substances 0.000 title abstract 2
- -1 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carb on yl}-2,2-dimethylpropyl]carbamate Chemical compound 0.000 title 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 abstract 3
- 229960002118 asunaprevir Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261643454P | 2012-05-07 | 2012-05-07 | |
| PCT/US2013/038770 WO2013169520A1 (en) | 2012-05-07 | 2013-04-30 | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014502405A1 true PH12014502405A1 (en) | 2015-01-12 |
Family
ID=48428670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014502405A PH12014502405A1 (en) | 2012-05-07 | 2014-10-27 | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carb on yl}-2,2-dimethylpropyl]carbamate |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20130302414A1 (https=) |
| EP (1) | EP2846780B1 (https=) |
| JP (1) | JP6276756B2 (https=) |
| KR (1) | KR20150004921A (https=) |
| CN (1) | CN104363899A (https=) |
| AR (1) | AR090954A1 (https=) |
| AU (1) | AU2013260005B2 (https=) |
| BR (1) | BR112014027676A2 (https=) |
| CA (1) | CA2872765A1 (https=) |
| CL (1) | CL2014003012A1 (https=) |
| CO (1) | CO7141457A2 (https=) |
| CY (1) | CY1120756T1 (https=) |
| DK (1) | DK2846780T3 (https=) |
| EA (1) | EA028749B1 (https=) |
| ES (1) | ES2688817T3 (https=) |
| HR (1) | HRP20181583T1 (https=) |
| IL (1) | IL235466B (https=) |
| LT (1) | LT2846780T (https=) |
| MX (1) | MX358545B (https=) |
| MY (1) | MY171378A (https=) |
| NZ (1) | NZ630248A (https=) |
| PE (1) | PE20142439A1 (https=) |
| PH (1) | PH12014502405A1 (https=) |
| PL (1) | PL2846780T3 (https=) |
| PT (1) | PT2846780T (https=) |
| RS (1) | RS57881B1 (https=) |
| SG (1) | SG11201406964QA (https=) |
| SI (1) | SI2846780T1 (https=) |
| SM (1) | SMT201800506T1 (https=) |
| TW (1) | TWI577392B (https=) |
| UY (1) | UY34785A (https=) |
| WO (1) | WO2013169520A1 (https=) |
| ZA (1) | ZA201408967B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2673870T3 (es) * | 2012-05-07 | 2018-06-26 | Bristol-Myers Squibb Holdings Ireland | Formulación de dosificación oral sólida de [(1S)-1-{[(2S,4R)-4-(7-cloro-4-metoxiisoquinolin-1-iloxi)-2-({(1R,2S)-1-[(ciclopropilsulfonil) carbamoil]-2-etenilciclopropil} carbamoil) pirrolidin-1-il] carbonil}-2,2-dimetil-propil] carbamato de 1,1-dimetiletilo |
| EA025560B1 (ru) | 2012-10-19 | 2017-01-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| WO2019130341A1 (en) * | 2017-12-26 | 2019-07-04 | Hetero Labs Limited | Capsule compositions comprising lopinavir and ritonavir |
| AU2019233606B2 (en) | 2018-03-14 | 2024-10-03 | KaNDy Therapeutics Limited | Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists |
| FI3897589T3 (fi) * | 2018-12-19 | 2026-01-13 | Corcept Therapeutics Inc | Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
| DE60132103T2 (de) * | 2000-10-31 | 2008-04-17 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US20110229438A1 (en) * | 2008-10-09 | 2011-09-22 | Anadys Pharmaceuticals, Inc. | Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
-
2013
- 2013-04-29 US US13/872,652 patent/US20130302414A1/en not_active Abandoned
- 2013-04-30 RS RS20181141A patent/RS57881B1/sr unknown
- 2013-04-30 WO PCT/US2013/038770 patent/WO2013169520A1/en not_active Ceased
- 2013-04-30 DK DK13722217.0T patent/DK2846780T3/en active
- 2013-04-30 NZ NZ630248A patent/NZ630248A/en not_active IP Right Cessation
- 2013-04-30 SI SI201331126T patent/SI2846780T1/sl unknown
- 2013-04-30 MY MYPI2014703294A patent/MY171378A/en unknown
- 2013-04-30 SM SM20180506T patent/SMT201800506T1/it unknown
- 2013-04-30 SG SG11201406964QA patent/SG11201406964QA/en unknown
- 2013-04-30 PE PE2014001988A patent/PE20142439A1/es not_active Application Discontinuation
- 2013-04-30 PT PT13722217T patent/PT2846780T/pt unknown
- 2013-04-30 JP JP2015511510A patent/JP6276756B2/ja not_active Expired - Fee Related
- 2013-04-30 BR BR112014027676A patent/BR112014027676A2/pt not_active IP Right Cessation
- 2013-04-30 ES ES13722217.0T patent/ES2688817T3/es active Active
- 2013-04-30 MX MX2014013220A patent/MX358545B/es active IP Right Grant
- 2013-04-30 EA EA201492039A patent/EA028749B1/ru not_active IP Right Cessation
- 2013-04-30 CA CA2872765A patent/CA2872765A1/en not_active Abandoned
- 2013-04-30 EP EP13722217.0A patent/EP2846780B1/en active Active
- 2013-04-30 PL PL13722217T patent/PL2846780T3/pl unknown
- 2013-04-30 CN CN201380023724.1A patent/CN104363899A/zh active Pending
- 2013-04-30 AU AU2013260005A patent/AU2013260005B2/en not_active Ceased
- 2013-04-30 HR HRP20181583TT patent/HRP20181583T1/hr unknown
- 2013-04-30 KR KR20147033971A patent/KR20150004921A/ko not_active Ceased
- 2013-04-30 LT LTEP13722217.0T patent/LT2846780T/lt unknown
- 2013-05-06 UY UY0001034785A patent/UY34785A/es unknown
- 2013-05-06 TW TW102116102A patent/TWI577392B/zh not_active IP Right Cessation
- 2013-05-06 AR ARP130101544A patent/AR090954A1/es unknown
-
2014
- 2014-10-27 PH PH12014502405A patent/PH12014502405A1/en unknown
- 2014-11-03 IL IL235466A patent/IL235466B/en active IP Right Grant
- 2014-11-06 CL CL2014003012A patent/CL2014003012A1/es unknown
- 2014-12-02 CO CO14265249A patent/CO7141457A2/es unknown
- 2014-12-05 ZA ZA2014/08967A patent/ZA201408967B/en unknown
-
2018
- 2018-10-15 CY CY181101051T patent/CY1120756T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502405A1 (en) | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carb on yl}-2,2-dimethylpropyl]carbamate | |
| PH12015501620A1 (en) | Pharmaceutical composition with improved bioavailability | |
| AU2013225533A8 (en) | Amido spirocyclic amide and sulfonamide derivatives | |
| HK1208150A1 (en) | Vaccine | |
| WO2015081085A3 (en) | Methods of treating a tauopathy | |
| EP4353289A3 (en) | Headgear assembly for breathing interface | |
| MX2013012542A (es) | Compuestos de amida y aplicacion farmaceutica para el mismo. | |
| WO2011138678A3 (en) | Compositions, gels and foams with rheology modulators and uses thereof | |
| HK1206055A1 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| WO2014011534A3 (en) | Cannula | |
| PL2964023T3 (pl) | Zastosowanie n-(2-metoksybenzoilo)- 4-[(metyloaminokarbonylo)amino]benzenosulfonamidu w kombinacji ze środkiem owadobójczym lub fungicydem dla zwiększenia plonów roślin | |
| MX2014009617A (es) | Polimorfos de n-(2-metoxibenzoil)-4-[(metilaminocarbonil)amino]ben cenosulfonamida. | |
| WO2015048503A3 (en) | N-arylmethyl sulfonamide negative modulators of nr2a | |
| IL237332A0 (en) | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of serious diseases such as depression, diabetes and Parkinson's disease | |
| WO2010046865A3 (en) | Ophthalmic administration of a composition including brimonidine as a mist | |
| WO2011054804A3 (en) | Skin care compositions comprising phenoxyalkyl amines | |
| MX352596B (es) | Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3´h-espiro[ciclohexan-1,1´-piran-[3,4,b] indol]-4-amina y paracetamol o propacetamol. | |
| CA2852067C (en) | Sugar chain-containing polymer, and sugar chain-containing polymer complex | |
| TH1401006625A (th) | สูตรผสมแคปซูลที่ละลายได้ของ 1,1-ไดเมธิลเอธิล[(1s)-1{[2s,4r)-4-(7-คลอโร-4เมธอกซีไอโซควิโนลิน-1-อิลออกซี)-2-({1r,2s)-1-[(ไซโคลโพรพิลซัลโฟนิล) คาร์บาโมอิล]-2-เอธีนิลไซโคลโพรพิล}คาร์บาโมอิล)ไพร์โรลิดิน-1-อิล]คาร์บอนิล}-2,2-ไดเมธิลโพรพิล]คาร์บาเมต | |
| WO2014099109A3 (en) | Plod-2 modulators and their use in the treatment of skin | |
| WO2012160713A8 (en) | Learning and memory improver | |
| CN105709225A (zh) | 一种用于治疗高眼压的药物 | |
| TH156288A (th) | สูตรผสมแคปซูลที่ละลายได้ของ 1,1-ไดเมธิลเอธิล[(1s)-1{[2s,4r)-4-(7-คลอโร-4เมธอกซีไอโซควิโนลิน-1-อิลออกซี)-2-({1r,2s)-1-[(ไซโคลโพรพิลซัลโฟนิล) คาร์บาโมอิล]-2-เอธีนิลไซโคลโพรพิล}คาร์บาโมอิล)ไพร์โรลิดิน-1-อิล]คาร์บอนิล}-2,2-ไดเมธิลโพรพิล]คาร์บาเมต | |
| HK1177430A1 (zh) | 使用间充质肝细胞的骨骼肌再生 | |
| UA46750U (uk) | Мікропризмова лінза комбінованої дії |